Preoperative radiotherapy in the management of retroperitoneal liposarcoma

Ecker, Brett L.; Peters, Madalyn G.; McMillan, Matthew T.; Sinnamon, Andrew J.; Zhang, P J; Fraker, Douglas L.; Levin, William P.; Roses, Robert E.; Karakousis, Giorgos C.

doi:10.1002/bjs.10305

Cited by 30 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, in a retrospective analysis, Ecker et al. described an improved survival in patients undergoing neoadjuvant radiotherapy 29 . The authors reported an improved overall survival of 129.2 months versus 84.3 months in patients treated with radiotherapy, particularly in cases of tumours with organ invasion.…”

Section: Discussionmentioning

confidence: 98%

Giant retroperitoneal liposarcoma: A case report and literature review

Herzberg

Niehaus

Holl‐Ulrich

et al. 2019

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

Retroperitoneal liposarcomas are a heterogeneous group of mesenchymal tumours that have a wide spectrum of histological subtypes and vague clinical presentations. Herein, we present the case of a 75-year-old man with anorexia, weight loss of 7 kg, and a growing abdominal circumference within a span of 6 weeks. Computed tomography of the abdomen and pelvis showed a large mass that filled almost the entire abdominal cavity. After consultation with a multidisciplinary tumour board, en bloc resection of the tumour was performed. In addition, the left kidney and a part of the left diaphragm were removed. The tumour measured 35 × 29 × 20.5 cm and weighed 11.6 kg. The histological report confirmed low-grade dedifferentiated liposarcoma with scarce atypical adipocytes, lipoblasts containing spindle cell, pleomorphic, and chondroid components. The patient had uneventful recovery and remained stable during the follow-up period. We report this case to highlight the need for customized surgical oncological measures in the treatment of solid abdominal tumours due to locoregional invasion that usually necessitates en bloc resection.

show abstract

Section: Discussionmentioning

confidence: 98%

Giant retroperitoneal liposarcoma: A case report and literature review

Herzberg

Niehaus

Holl‐Ulrich

et al. 2019

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Although surgery is considered the most effective treatment for RPLPS, some studies have also tried new adjuvant treatments. These studies shown that preoperative neoadjuvant radiotherapy can prolong the survival of RPLPS, especially in patients with high-risk pathological types [22], and reduce the possibility of local recurrence [23]. MD Anderson Cancer Center reported that combined chemotherapy in patients with RP DDLPS produced a response rate of 24% [24].…”

Section: Discussionmentioning

confidence: 99%

Resection outcomes for primary and local recurrent retroperitoneal liposarcoma patients

Yan

Xia

et al. 2020

Preprint

View full text Add to dashboard Cite

Aim: The clinical characteristics of primary retroperitoneal liposarcoma(PR RPLPS) and local recurrent retroperitoneal liposarcoma(LR RPLPS) cases were compared to determine related factors involved in postoperative survival.Methods: A total of 90 patients who underwent surgery between 2006 and 2013 were included in this study. Clinicopathological data that was prospectively gathered was analyzed to identify factors associated with overall survival and progression-free survival.Results: The PR cases showed a higher complete resection rate when compared to the LR group. The LR group showed a greater number that were poorly differentiated and highly malignant. More blood loss was observed in the LR compared to the PR group. Multivariate analysis suggested that blood loss and tumor grade were prognostic factors for OS and PFS of the PR group, but extent of resection was a prognostic factor only for OS. In the LR group, the extent of resection was a significant prognostic factor associated with OS, whereas tumor grade was associated with PFS.Conclusions: Complete surgical resection is the most important factor for the survival of RPLPS patients. Tumor grade is an independent prognostic factor for PFS. In PR RPLPS, poor tumor classification and increased intraoperative bleeding are associated with a poor prognosis.

show abstract

“…Local recurrence often occurs even after complete excision. 18 In addition, this kind of tumor is insensitive to chemoradiotherapy. Therefore, it is particularly important to find effective therapeutic targets and carry out combined treatment.…”

Section: Discussionmentioning

confidence: 99%

<p>Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance</p>

Zhang¹,

Liang²,

Cui³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Retroperitoneal liposarcoma (RLPS) is a rare tumor with high recurrence rate. Ribonucleotide reductase small subunit M2 (RRM2) protein is essential for DNA synthesis and replication. Our previous study has demonstrated that RRM2 downregulation inhibited the proliferation of RLPS cells, but further association between RRM2 and RLPS and relevant mechanisms remains to be explored. Methods: RRM2 expression was evaluated in RLPS tumor tissues and cell lines by using real-time PCR and immunohistochemical analysis. The effect of RRM2 downregulation on cell proliferation, apoptosis, cell cycle, cell migration and invasion was tested by lentivirus. The effect of RRM2 inhibition on tumor growth in vivo was assessed by using patientderived tumor xenograft (PDX) of RLPS and RRM2 inhibitor. The underlying mechanisms of RRM2 in RLPS were explored by protein microarray and Western blotting. Results: The results showed that RRM2 mRNA expression was higher in RLPS tissues than in normal fatty tissues (P<0.001). RRM2 expression was higher in the dedifferentiated, myxoid/round cell, and pleomorphic subtypes (P=0.027), and it was also higher in the highgrade RLPS tissues compared to that in the low-grade RLPS tissues (P=0.004). There was no correlation between RRM2 expression and overall survival (OS) or disease-free survival (DFS) in this group of RLPS patients (P>0.05). RRM2 downregulation inhibited cell proliferation, promoted cell apoptosis, facilitated cell cycle from G1 phase to S phase and inhibited cell migration and invasion. Inhibition of RRM2 suppressed tumor growth in NOD/ SCID mice. Protein microarray and Western blot verification showed that activity of Akt/ mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation. Conclusion: RRM2 was overexpressed in RLPS tissues, and downregulation of RRM2 could inhibit RLPS progression. In addition, suppression of RRM2 is expected to be a promising treatment for RLPS patients.

show abstract

Preoperative radiotherapy in the management of retroperitoneal liposarcoma

Abstract: NRT improved survival in patients undergoing surgery for retroperitoneal liposarcoma, particularly those with high-risk pathological features.

Cited by 30 publications

References 27 publications

Giant retroperitoneal liposarcoma: A case report and literature review

Giant retroperitoneal liposarcoma: A case report and literature review

Resection outcomes for primary and local recurrent retroperitoneal liposarcoma patients

<p>Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance</p>

Contact Info

Product

Resources

About